SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 20, 2017, Pages E4002-E4009

  Taracanova, Alexandra ^a   Alevizos, Mihail ^a   Karagkouni, Anna ^a   Weng, Zuiy ^a   Norwitz, Errol ^a   Conti, Pio ^b   Leeman, Susan E ^c   Theoharides, Theoharis C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Interleukin 33; Mast cells; Substance P; Tumor necrosis factor

Indexed keywords

5,7,3,4' TETRAMETHOXYFLAVONE; FLAVONE DERIVATIVE; I KAPPA B KINASE ALPHA; INTERLEUKIN 33; MEMBRANE PROTEIN; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUTRALIZING ANTIBODY; RECEPTOR; SMALL INTERFERING RNA; SUBSTANCE P; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYLOXY)-2-PHENYLPIPERIDINE; BIPHENYL DERIVATIVE; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; NEUROKININ 1 RECEPTOR; PIPERIDINE DERIVATIVE; TNF PROTEIN, HUMAN;

ARTICLE; CELLULAR SECRETION; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAST CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHESIS; UMBILICAL CORD BLOOD; BIOSYNTHESIS; MAPK SIGNALING; METABOLISM; SECRETION (PROCESS); TUMOR CELL LINE;

BIPHENYL COMPOUNDS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MAP KINASE SIGNALING SYSTEM; MAST CELLS; NF-KAPPA B; PIPERIDINES; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85019836199     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1524845114     Document Type: Article

References (67)

1. Chang MM, Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 245:4784-4790.
2. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE (2006) The role of neuropeptides in psoriasis. Br J Dermatol 155:876-882.
3. Douglas SD, Leeman SE (2011) Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci 1217:83-95.
4. O'Connor TM, et al. (2004) The role of substance P in inflammatory disease. J Cell Physiol 201:167-180.
5. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW (2014) Tachykinins and their receptors: Contributions to physiological control and the mechanisms of disease. Physiol Rev 94:265-301.
6. Richard AC, et al. (2015) The TNF-family cytokine TL1A: From lymphocyte costimulator to disease co-conspirator. J Leukoc Biol 98:333-45.
7. Mu?oz M, Cove?as R (2014) Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids 46:1727-1750.
8. Fewtrell CMS, et al. (1982) The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol 330:393-411.
9. Ansel JC, Brown JR, Payan DG, Brown MA (1993) Substance P selectively activates TNF-α gene expression in murine mast cells. J Immunol 150:4478-4485.
10. Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M (1998) Human skin mast cells produce TNF-alpha by substance P. Int Arch Allergy Immunol 117:48-51.
11. Okabe T, Hide M, Koro O, Yamamoto S (2000) Substance P induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. Eur J Pharmacol 398:309-315.
12. Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373:163-172.
13. Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6:135-142.
14. Rottem M, Mekori YA (2005) Mast cells and autoimmunity. Autoimmun Rev 4:21-27.
15. Theoharides TC, Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146:1-12.
16. Theoharides TC, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107: 4448-4453.
17. Sumpter TL, et al. (2015) Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. J Allergy Clin Immunol 135:1019-30.e8.
18. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
19. Dinarello CA (2003) Setting the cytokine trap for autoimmunity. Nat Med 9:20-22.
20. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P (2015) Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 354:24-31.
21. Saluja R, et al. (2015) The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol 63:80-85.
22. Saluja R, Hawro T, Eberle J, Church MK, Maurer M (2014) Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J Biol Regul Homeost Agents 28:575-585.
23. Moulin D, et al. (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40:216-225.
24. Silver MR, et al. (2010) IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 59:207-218.
25. Babina M, Guhl S, Artuc M, Trivedi NN, Zuberbier T (2016) Phenotypic variability in human skin mast cells. Exp Dermatol 25:434-439.
26. Louten J, et al. (2011) Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 23:307-315.
27. Sj?berg LC, Gregory JA, Dahl?n SE, Nilsson GP, Adner M (2015) Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells. Allergy 70:514-521.
28. Meephansan J, et al. (2013) Expression of IL-33 in the epidermis: The mechanism of induction by IL-17. J Dermatol Sci 71:107-114.
29. Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M (2012) Regulation of IL-33 expression by IFN-? and tumor necrosis factor-? in normal human epidermal keratinocytes. J Invest Dermatol 132:2593-2600.
30. Balato A, et al. (2012) IL-33 is secreted by psoriatic keratinocytes and induces proinflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 21: 892-894.
31. Mitsui A, et al. (2015) Serum IL-33 levels are increased in patients with psoriasis 1. Clin Exp Dermatol 41:183-9.
32. Gordon JR, Galli SJ (1990) Mast cells as a source of both preformed and immunologically inducible TNF-?/cachectin. Nature 346:274-276.
33. Gordon JR, Galli SJ (1991) Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI: A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J Exp Med 174:103-107.
34. Zhang B, et al. (2012) Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol 159:23-32.
35. Nakae S, et al. (2005) Mast cells enhance T cell activation: Importance of mast cellderived TNF. Proc Natl Acad Sci USA 102:6467-6472.
36. Kempuraj D, et al. (2008) Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br J Pharmacol 155:1076-1084.
37. Weng Z, Patel AB, Vasiadi M, Therianou A, Theoharides TC (2014) Luteolin inhibits human keratinocyte activation and decreases NF-?B induction that is increased in psoriatic skin. PLoS One 9:e90739.
38. Guhl S, Lee HH, Babina M, Henz BM, Zuberbier T (2005) Evidence for a restricted rather than generalized stimulatory response of skin-derived human mast cells to substance P. J Neuroimmunol 163:92-101.
39. Drube S, et al. (2010) The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 115:3899-3906.
40. Theoharides TC, et al. (2012) Mast cells and inflammation. Biochim Biophys Acta 1822: 21-33.
41. Kritas SK, et al. (2013) Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 27:655-660.
42. Rijnierse A, Nijkamp FP, Kraneveld AD (2007) Mast cells and nerves tickle in the tummy: Implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 116:207-235.
43. Kritas SK, et al. (2013) Impact of mast cells on the skin. Int J Immunopathol Pharmacol 26:855-859.
44. Costanza M, Colombo MP, Pedotti R (2012) Mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci 13:15107-15125.
45. Castells M (2006) Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 26:465-485.
46. Castells M, Austen KF (2002) Mastocytosis: Mediator-related signs and symptoms. Int Arch Allergy Immunol 127:147-152.
47. Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC (2016) Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 356:664-672.
48. Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364-371.
49. Singh UP, et al. (2016) Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine 77:44-49.
50. Victor FC, Gottlieb AB, Menter A (2003) Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 21:392-397.
51. Probert L (2015) TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience 302:2-22.
52. Maintz L, et al. (2011) Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis. Allergy 66:862-869.
53. Origuchi T, et al. (2011) Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol 21:244-250.
54. Kourelis T, Manola A, Theoharides TC (2010) Umbilical cord-derived mast cells as models for the study of inflammatory diseases. Pregnancy and Placental Stem Cells, eds Cetrulo CL, Cetrulo KJ, Cetrulo CLJ (Wiley-Blackwell, Hoboken, NJ), pp 103-145.
55. Azzolina A, Bongiovanni A, Lampiasi N (2003) Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochim Biophys Acta 1643:75-83.
56. Lefran?ais E, et al. (2014) Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci USA 111: 15502-15507.
57. Weng Z, Patel AB, Panagiotidou S, Theoharides TC (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 135: 1044-52.e5.
58. Harwood M, et al. (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179-2205.
59. Taliou A, Zintzaras E, Lykouras L, Francis K (2013) An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther 35:592-602.
60. Theoharides TC (2017) Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. Int J Immunopathol Pharmacol, in press.
61. Milovanovic M, et al. (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 52:89-99.
62. M?ller-Ladner U, Gay RE, Gay S (2002) Role of nuclear factor kappaB in synovial inflammation. Curr Rheumatol Rep 4:201-207.
63. Kakkar R, Lee RT (2008) The IL-33/ST2 pathway: Therapeutic target and novel biomarker. Nat Rev Drug Discov 7:827-840.
64. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179.
65. Kirshenbaum AS, et al. (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia: Activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27:677-682.
66. Kempuraj D, et al. (2004) Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145: 43-48.
67. Kempuraj D, et al. (1999) Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 93:3338-3346.